venlafaxine besylate Drug Patent Profile
✉ Email this page to a colleague
When do Venlafaxine Besylate patents expire, and when can generic versions of Venlafaxine Besylate launch?
Venlafaxine Besylate is a drug marketed by Almatica and is included in one NDA. There is one patent protecting this drug.
The generic ingredient in VENLAFAXINE BESYLATE is venlafaxine besylate. There are seventy-one drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the venlafaxine besylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Venlafaxine Besylate
A generic version of venlafaxine besylate was approved as venlafaxine besylate by ALMATICA on June 29th, 2022.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for venlafaxine besylate?
- What are the global sales for venlafaxine besylate?
- What is Average Wholesale Price for venlafaxine besylate?
Summary for venlafaxine besylate
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 3 |
| Clinical Trials: | 1 |
| Patent Applications: | 9 |
| DailyMed Link: | venlafaxine besylate at DailyMed |
Recent Clinical Trials for venlafaxine besylate
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Alphacait, LLC | Phase 2 |
| Haining Health-Coming Biotech Co., Ltd. | Phase 2 |
Pharmacology for venlafaxine besylate
| Drug Class | Serotonin and Norepinephrine Reuptake Inhibitor |
| Mechanism of Action | Norepinephrine Uptake Inhibitors Serotonin Uptake Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for venlafaxine besylate
US Patents and Regulatory Information for venlafaxine besylate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Almatica | VENLAFAXINE BESYLATE | venlafaxine besylate | TABLET, EXTENDED RELEASE;ORAL | 215429-001 | Jun 29, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for venlafaxine besylate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Almatica | VENLAFAXINE BESYLATE | venlafaxine besylate | TABLET, EXTENDED RELEASE;ORAL | 215429-001 | Jun 29, 2022 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Premature patent expiration for: VENLAFAXINE BESYLATE
Expiration due to failure to pay maintenance fee
| Patent Number | Tradename | Expiration Date |
|---|---|---|
| ⤷ Sign Up | VENLAFAXINE BESYLATE | ⤷ Sign Up |
International Patents for venlafaxine besylate
See the table below for patents covering venlafaxine besylate around the world.
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
